OncoMatch/Clinical Trials/NCT05687136
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
Is NCT05687136 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Peposertib and Tuvusertib for advanced malignant solid neoplasm.
Treatment: Peposertib · Tuvusertib — This phase I trial tests the safety, side effects and best dose of peposertib (M3814) in combination with tuvusertib (M1774) in treating patients with solid tumors that have spread to other places in the body (advanced). Peposertib and tuvusertib stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: ARID1A mutation
Required: ARID1B mutation
Required: ARID2 mutation
Required: ATM inactivating mutation
Required: ATRX mutation
Required: CCNE1 amplification
Required: DAXX mutation
Required: FBXW7 mutation
Required: MYC amplification
Required: PBRM1 mutation
Required: SMARCA2 mutation
Required: SMARCA4 mutation
Required: SMARCB1 mutation
Required: SS18 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Hemoglobin >= 9 g/dL; Absolute neutrophil count >= 1,500/mcL; Platelets >= 100,000/mcL
Kidney function
Glomerular filtration rate (GFR) >= 60 mL/min/1.73m^2
Liver function
Total bilirubin <= 1.5 x institutional ULN; AST/ALT <= 3 x ULN or <= 5 x ULN if liver metastases are present
Cardiac function
QTcF (using the Fridericia correction calculation) of < 470 msec; NYHA class 2B or better
Hemoglobin >= 9 g/dL. Absolute neutrophil count >= 1,500/mcL. Platelets >= 100,000/mcL. Total bilirubin <= 1.5 x institutional ULN. AST/ALT <= 3 x ULN or <= 5 x ULN if liver metastases are present. Glomerular filtration rate (GFR) >= 60 mL/min/1.73m^2. QTcF (using the Fridericia correction calculation) of >= 470 msec. NYHA class 2B or better.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- National Cancer Institute Developmental Therapeutics Clinic · Bethesda, Maryland
- National Institutes of Health Clinical Center · Bethesda, Maryland
- Massachusetts General Hospital Cancer Center · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
- NYU Langone Hospital - Long Island · Mineola, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify